Corbus Pharmaceuticals, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- 1
- Market Cap
- $689.3M
- Website
- http://www.corbuspharma.com
First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.
- Conditions
- Solid Tumor
- Interventions
- Drug: CRB-601 monoclonal antibodyDrug: Anti-PD-1 monoclonal antibodyRadiation: Immune-priming single lesion SBRT
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT06603844
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธSCRI - Arizona Oncology Associates, Tucson, Arizona, United States
๐บ๐ธThe University of Arizona Cancer Center, Tucson, Arizona, United States
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: CRB-701
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT06265727
- Locations
- ๐บ๐ธ
O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama, United States
๐บ๐ธCity of Hope Cancer Center, Duarte, California, United States
๐บ๐ธMoores Cancer Centre at UC San Diego Health, San Diego, California, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
- Conditions
- Dermatomyositis
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03813160
- Locations
- ๐บ๐ธ
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธUniversity of Pittsburgh, Division of Rheumatology, Pittsburgh, Pennsylvania, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT03451045
- Locations
- ๐ฆ๐น
Cystic Fibrosis Centre Innsbruck Medical University of Innsbruck, Dept. for Child and Adolescent Health, University Clinic for Paediatrics, Cardiology, Pneumology, Allergology, Cystic Fibrosis, Innsbruck, Austria
๐ฆ๐นMedical University of Vienna, Vienna, Austria
๐ง๐ชUniversitair Ziekenhuis Brussel, Brussels, Belgium
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT03398837
- Locations
- ๐บ๐ธ
John Hopkins University, Scleroderma Center, Baltimore, Maryland, United States
๐บ๐ธThe Steffens Scleroderma at The Center for Rheumatology, Albany, New York, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02466243
- Locations
- ๐บ๐ธ
University of Pennsylvania Perlman School of Medicine, Philadelphia, Pennsylvania, United States
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02465437
- Locations
- ๐บ๐ธ
Arthritis Association of Southern CA, Los Angeles, California, United States
๐บ๐ธStanford University, Palo Alto, California, United States
๐บ๐ธJohn Hopkins Scleroderma Center, Baltimore, Maryland, United States
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT02465450
- Locations
- ๐บ๐ธ
New York Medical College, Valhalla, New York, United States
๐ฌ๐งBelfast City Hospital, Belfast, United Kingdom
๐ต๐ฑInstytut Gruลบlicy i Chorรณb Pลuc I Klinika Chorรณb Pลuc, Warszawa, Poland